Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Hackensack Meridian Health
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
This description comes directly from the study's public registry record.
Lauren Finaldi · 551-996-5228 · Lauren.Finaldi@hmhn.org
Suzanne Kosky · 551-996-3986 · Suzanne.Kosky@hmhn.org
Always discuss trial participation with your own doctor first.
| Lombardi Comprehensive Cancer Center, Georgetown University | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| John Theurer Cancer Center, Hackensack Meridian Health | Hackensack, New Jersey, United States | Recruiting |
| Jersey Shore University Medical Center | Neptune City, New Jersey, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05715229